Trial Profile
Phase II study of ramucirumab and irinotecan combination therapy as second-line treatment in patients with metastatic or advanced gastric cancer
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 24 Aug 2022
Price :
$35
*
At a glance
- Drugs Irinotecan (Primary) ; Ramucirumab (Primary)
- Indications Adenocarcinoma; Gastric cancer
- Focus Therapeutic Use
- Acronyms HGCSG 1603
- Sponsors Eli Lilly Japan
- 05 Aug 2022 Results published in the Oncologist
- 03 Jul 2021 Results of updated analysis of the HGCSG1603 trial, presented at the 23rd World Congress on Gastrointestinal Cancer
- 17 Jan 2021 Primary endpoint (progression-free survival rate at six months (PFS rate at 6 months)) has not been met.